Oliver D Howes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3797796/publications.pdf

Version: 2024-02-01

408 papers	29,870 citations	4641 85 h-index	6818 155 g-index
438 all docs	438 docs citations	438 times ranked	22337 citing authors

#	Article	IF	Citations
1	The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway. Schizophrenia Bulletin, 2009, 35, 549-562.	2.3	2,149
2	The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment. Archives of General Psychiatry, 2012, 69, 776-86.	13.8	769
3	Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2016, 30, 495-553.	2.0	755
4	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry, 2017, 174, 216-229.	4.0	685
5	Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia. Archives of General Psychiatry, 2009, 66, 13.	13.8	653
6	Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet, The, 2014, 383, 1677-1687.	6.3	638
7	Glutamate and dopamine in schizophrenia: An update for the 21st century. Journal of Psychopharmacology, 2015, 29, 97-115.	2.0	596
8	Schizophreniaâ€"An Overview. JAMA Psychiatry, 2020, 77, 201.	6.0	569
9	Cognitive Functioning in Prodromal Psychosis. Archives of General Psychiatry, 2012, 69, 562-71.	13.8	567
10	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2020, 7, 64-77.	3.7	506
11	Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness. Psychopharmacology, 2016, 233, 1637-1650.	1.5	476
12	Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends in Neurosciences, 2019, 42, 205-220.	4.2	441
13	The Role of Genes, Stress, and Dopamine in the Development of Schizophrenia. Biological Psychiatry, 2017, 81, 9-20.	0.7	416
14	Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [¹¹C]PBR28 PET Brain Imaging Study. American Journal of Psychiatry, 2016, 173, 44-52.	4.0	382
15	Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain, Behavior, and Immunity, 2020, 87, 901-909.	2.0	381
16	The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Molecular Psychiatry, 2017, 22, 666-679.	4.1	347
17	Impaired Glucose Homeostasis in First-Episode Schizophrenia. JAMA Psychiatry, 2017, 74, 261.	6.0	328
18	Dopamine Synthesis Capacity Before Onset of Psychosis: A Prospective [¹⁸F]-DOPA PET Imaging Study. American Journal of Psychiatry, 2011, 168, 1311-1317.	4.0	321

#	Article	IF	Citations
19	Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry, 2020, 19, 15-33.	4.8	301
20	Dopamine Synthesis Capacity in Patients With Treatment-Resistant Schizophrenia. American Journal of Psychiatry, 2012, 169, 1203-1210.	4.0	291
21	Stress resilience during the coronavirus pandemic. European Neuropsychopharmacology, 2020, 35, 12-16.	0.3	285
22	Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. British Journal of Psychiatry, 2012, 201, 481-485.	1.7	280
23	Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. Biological Psychiatry, 2014, 75, e11-e13.	0.7	280
24	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2020, 34, 3-78.	2.0	259
25	Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Molecular Psychiatry, 2011, 16, 885-886.	4.1	255
26	Association of Stimulant Use With Dopaminergic Alterations in Users of Cocaine, Amphetamine, or Methamphetamine. JAMA Psychiatry, 2017, 74, 511.	6.0	255
27	The effects of Î”9-tetrahydrocannabinol on the dopamine system. Nature, 2016, 539, 369-377.	13.7	251
28	Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia. JAMA Psychiatry, 2017, 74, 1104.	6.0	247
29	Abnormal Frontostriatal Interactions in People With Prodromal Signs of Psychosis. Archives of General Psychiatry, 2010, 67, 683.	13.8	235
30	Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging. Current Pharmaceutical Design, 2009, 15, 2550-2559.	0.9	213
31	30 Years on: How the Neurodevelopmental Hypothesis of Schizophrenia Morphed Into the Developmental Risk Factor Model of Psychosis. Schizophrenia Bulletin, 2017, 43, 1190-1196.	2.3	213
32	Presynaptic Striatal Dopamine Dysfunction in People at Ultra-high Risk for Psychosis: Findings in a Second Cohort. Biological Psychiatry, 2013, 74, 106-112.	0.7	208
33	Dopaminergic basis of salience dysregulation in psychosis. Trends in Neurosciences, 2014, 37, 85-94.	4.2	204
34	Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychological Medicine, 2016, 46, 3231-3240.	2.7	202
35	Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychological Medicine, 2017, 47, 1981-1989.	2.7	200
36	Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry, 2004, 184, 503-508.	1.7	198

#	Article	IF	Citations
37	Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Molecular Psychiatry, 2011, 16, 67-75.	4.1	198
38	Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2018, 32, 3-29.	2.0	196
39	Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?. British Journal of Psychiatry, 2016, 209, 361-365.	1.7	193
40	Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Translational Psychiatry, 2017, 7, e1024-e1024.	2.4	193
41	The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophrenia, 2020, 6, 1.	2.0	193
42	Defining the Locus of Dopaminergic Dysfunction in Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. Schizophrenia Bulletin, 2018, 44, 1301-1311.	2.3	187
43	The methodology of TSPO imaging with positron emission tomography. Biochemical Society Transactions, 2015, 43, 586-592.	1.6	186
44	Neural and Behavioral Correlates of Aberrant Salience in Individuals at Risk for Psychosis. Schizophrenia Bulletin, 2013, 39, 1328-1336.	2.3	180
45	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology, 2020, 172, 107704.	2.0	180
46	Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Molecular Psychiatry, 2019, 24, 549-561.	4.1	179
47	A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA Psychiatry, 2017, 74, 1206.	6.0	178
48	Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophrenia Bulletin, 2016, 42, 744-752.	2.3	174
49	Dopaminergic Function in Cannabis Users and Its Relationship to Cannabis-Induced Psychotic Symptoms. Biological Psychiatry, 2014, 75, 470-478.	0.7	170
50	Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies. Neuroscience and Biobehavioral Reviews, 2014, 45, 233-245.	2.9	167
51	A neurobiological hypothesis for the classification of schizophrenia: type a (hyperdopaminergic) and type B (normodopaminergic). British Journal of Psychiatry, 2014, 205, 1-3.	1.7	166
52	The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Molecular Psychiatry, 2018, 23, 59-69.	4.1	165
53	Auditory verbal hallucinations and continuum models of psychosis: A systematic review of the healthy voice-hearer literature. Clinical Psychology Review, 2017, 51, 125-141.	6.0	161
54	Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2019, 80, .	1.1	157

#	Article	IF	Citations
55	A neuroimaging biomarker for striatal dysfunction in schizophrenia. Nature Medicine, 2020, 26, 558-565.	15.2	152
56	Neuroinflammation in schizophrenia: meta-analysis ofin vivomicroglial imaging studies. Psychological Medicine, 2019, 49, 2186-2196.	2.7	151
57	The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neuroscience and Biobehavioral Reviews, 2009, 33, 1109-1132.	2.9	150
58	Pathways to schizophrenia: the impact of environmental factors. International Journal of Neuropsychopharmacology, 2004, 7, S7-S13.	1.0	148
59	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 2020, 11, 246.	5.8	148
60	Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis. Lancet Psychiatry,the, 2020, 7, 344-353.	3.7	147
61	Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain, 2013, 136, 3242-3251.	3.7	146
62	Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration. Brain, 2018, 141, 459-471.	3.7	143
63	Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends in Pharmacological Sciences, 2008, 29, 91-98.	4.0	138
64	Altered Relationship Between Hippocampal Glutamate Levels and Striatal Dopamine Function in Subjects at Ultra High Risk of Psychosis. Biological Psychiatry, 2010, 68, 599-602.	0.7	125
65	Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Molecular Psychiatry, 2019, 24, 776-794.	4.1	124
66	The testâ€“retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. NeuroImage, 2010, 50, 524-531.	2.1	121
67	Transition to Psychosis Associated With Prefrontal and Subcortical Dysfunction in Ultra High-Risk Individuals. Schizophrenia Bulletin, 2012, 38, 1268-1276.	2.3	120
68	Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study. Molecular Psychiatry, 2019, 24, 1502-1512.	4.1	120
69	Reduced mismatch negativity predates the onset of psychosis. Schizophrenia Research, 2012, 134, 42-48.	1.1	119
70	Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. British Journal of Psychiatry, 2007, 191, s13-s18.	1.7	118
71	Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis. British Journal of Psychiatry, 2017, 211, 339-349.	1.7	118
72	Treatment resistance in psychiatry: state of the art and new directions. Molecular Psychiatry, 2022, 27, 58-72.	4.1	117

#	Article	IF	Citations
73	A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis. Schizophrenia Bulletin, 2019, 45, 1120-1133.	2.3	113
74	Mapping vulnerability to bipolar disorder: a systematic review and meta-analysis of neuroimaging studies. Journal of Psychiatry and Neuroscience, 2012, 37, 170-184.	1.4	112
75	Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. Lancet Psychiatry,the, 2016, 3, 451-463.	3.7	106
76	Practitioner attitudes to clozapine initiation. Acta Psychiatrica Scandinavica, 2014, 130, 16-24.	2.2	105
77	Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis. American Journal of Psychiatry, 2016, 173, 392-399.	4.0	104
78	Further human evidence for striatal dopamine release induced by administration of âˆ†9-tetrahydrocannabinol (THC): selectivity to limbic striatum. Psychopharmacology, 2015, 232, 2723-2729.	1.5	103
79	Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data. Biological Psychiatry, 2018, 84, 433-442.	0.7	103
80	Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia. JAMA Network Open, 2020, 3, e204693.	2.8	103
81	Consensus statement on the use of clozapine during the COVID-19 pandemic. Journal of Psychiatry and Neuroscience, 2020, 45, 222-223.	1.4	102
82	Dopamine and the aberrant salience hypothesis of schizophrenia. World Psychiatry, 2016, 15, 3-4.	4.8	101
83	Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: systematic review and meta-analysis of imaging studies. British Journal of Psychiatry, 2014, 204, 420-429.	1.7	98
84	The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review. Translational Psychiatry, 2017, 7, e1015-e1015.	2.4	98
85	Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study. Neuropsychopharmacology, 2017, 42, 941-950.	2.8	98
86	The brain GABA-benzodiazepine receptor alpha-5 subtype in autism spectrum disorder: A pilot [11C]Ro15-4513 positron emission tomography study. Neuropharmacology, 2013, 68, 195-201.	2.0	97
87	The clinical significance of duration of untreated psychosis: an umbrella review and randomâ€effects metaâ€analysis. World Psychiatry, 2021, 20, 75-95.	4.8	97
88	A comprehensive review and model of putative prodromal features of bipolar affective disorder. Psychological Medicine, 2011, 41, 1567-1577.	2.7	92
89	The relationship between cortical glutamate and striatal dopamine in first-episode psychosis: a cross-sectional multimodal PET and magnetic resonance spectroscopy imaging study. Lancet Psychiatry,the, 2018, 5, 816-823.	3.7	89
90	Abnormal P300 in people with high risk of developing psychosis. NeuroImage, 2008, 41, 553-560.	2.1	87

#	Article	IF	Citations
91	The link between dopamine function and apathy in cannabis users: an [18F]-DOPA PET imaging study. Psychopharmacology, 2014, 231, 2251-2259.	1.5	86
92	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 451-489.	3.3	86
93	Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies. Journal of Neural Transmission, 2019, 126, 1637-1651.	1.4	84
94	Cannabis use and transition to psychosis in people at ultra-high risk. Psychological Medicine, 2014, 44, 2503-2512.	2.7	83
95	Dopaminergic Function in the Psychosis Spectrum: An [18F]-DOPA Imaging Study in Healthy Individuals With Auditory Hallucinations. Schizophrenia Bulletin, 2013, 39, 807-814.	2.3	80
96	Adversity in childhood linked to elevated striatal dopamine function in adulthood. Schizophrenia Research, 2016, 176, 171-176.	1.1	77
97	Sexual Function and Gonadal Hormones in Patients Taking Antipsychotic Treatment for Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychiatry, 2007, 68, 361-367.	1.1	77
98	Vitamin D deficiency in first episode psychosis: A caseâ€“control study. Schizophrenia Research, 2013, 150, 533-537.	1.1	76
99	Relationship Between Brain Glutamate Levels and Clinical Outcome in Individuals at Ultra High Risk of Psychosis. Neuropsychopharmacology, 2014, 39, 2891-2899.	2.8	76
100	Antipsychotic plasma levels in the assessment of poor treatment response inÂschizophrenia. Acta Psychiatrica Scandinavica, 2018, 137, 39-46.	2.2	76
101	A Prospective Study of Impairment in Glucose Control Caused by Clozapine Without Changes in Insulin Resistance. American Journal of Psychiatry, 2004, 161, 361-363.	4.0	75
102	The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. Journal of Affective Disorders, 2015, 186, 358-366.	2.0	75
103	Mesolimbic Dopamine Function Is Related to Salience Network Connectivity: An Integrative Positron Emission Tomography and Magnetic Resonance Study. Biological Psychiatry, 2019, 85, 368-378.	0.7	72
104	Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level. JAMA Psychiatry, 2021, 78, 667.	6.0	72
105	Abnormal Relationship Between Medial Temporal Lobe and Subcortical Dopamine Function in People With an Ultra High Risk for Psychosis. Schizophrenia Bulletin, 2012, 38, 1040-1049.	2.3	71
106	Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort. Schizophrenia Bulletin, 2018, 44, 1323-1331.	2.3	70
107	Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2019, 76, 199.	6.0	69
108	Heterogeneity of Striatal Dopamine Function in Schizophrenia: Meta-analysis of Variance. Biological Psychiatry, 2020, 87, 215-224.	0.7	69

#	Article	IF	Citations
109	Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophrenia Research, 2008, 106, 148-155.	1.1	66
110	Long-Term Heavy Ketamine Use is Associated with Spatial Memory Impairment and Altered Hippocampal Activation. Frontiers in Psychiatry, 2014, 5, 149.	1.3	65
111	Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. British Journal of Psychiatry, 2015, 207, 130-134.	1.7	65
112	Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy. American Journal of Human Genetics, 2016, 98, 735-743.	2.6	65
113	Dopaminergic basis for signaling belief updates, but not surprise, and the link to paranoia. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E10167-E10176.	3.3	65
114	Sex difference in brain CB1 receptor availability in man. NeuroImage, 2019, 184, 834-842.	2.1	65
115	Opposite Effects of Catechol-O-Methyltransferase Val158Met on Cortical Function in Healthy Subjects and Patients with Schizophrenia. Biological Psychiatry, 2009, 65, 473-480.	0.7	63
116	Interpersonal sensitivity in the at-risk mental state for psychosis. Psychological Medicine, 2012, 42, 1835-1845.	2.7	63
117	Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Molecular Psychiatry, 2012, 17, 1254-1260.	4.1	63
118	Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology, 2020, 45, 622-631.	2.8	63
119	Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Molecular Psychiatry, 2021, 26, 2562-2576.	4.1	60
120	Functional Outcome in People at High Risk for Psychosis Predicted by Thalamic Glutamate Levels and Prefronto-Striatal Activation. Schizophrenia Bulletin, 2015, 41, 429-439.	2.3	59
121	Aberrant Salience, Information Processing, and Dopaminergic Signaling in People at Clinical High Risk for Psychosis. Biological Psychiatry, 2020, 88, 304-314.	0.7	59
122	Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance. Biological Psychiatry, 2022, 92, 501-513.	0.7	59
123	Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia â€"Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group. Schizophrenia Bulletin, 2020, 46, 1459-1470.	2.3	58
124	Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2021, 82, .	1.1	58
125	Bone Mineral Density and Its Relationship to Prolactin Levels in Patients Taking Antipsychotic Treatment. Journal of Clinical Psychopharmacology, 2005, 25, 259-261.	0.7	57
126	History of cannabis use is not associated with alterations in striatal dopamine D₂/D₃ receptor availability. Journal of Psychopharmacology, 2012, 26, 144-149.	2.0	57

#	Article	IF	Citations
127	Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors. Scientific Reports, 2017, 7, 15025.	1.6	57
128	Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. Psychopharmacology, 2016, 233, 1605-1621.	1.5	54
129	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biological Psychiatry, 2019, 85, 79-87.	0.7	54
130	Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.. Translational Psychiatry, 2017, 7, e1027-e1027.	2.4	53
131	GABA-A receptor differences in schizophrenia: a positron emission tomography study using [11C]Ro154513. Molecular Psychiatry, 2021, 26, 2616-2625.	4.1	53
132	The effects of psychosocial stress on dopaminergic function and the acute stress response. ELife, 2019, 8, .	2.8	53
133	Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychological Medicine, 2011, 41, 2331-2338.	2.7	52
134	From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments. Current Pharmaceutical Design, 2012, 18, 459-465.	0.9	51
135	Neuropathological changes in the substantia nigra in schizophrenia but not depression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 285-296.	1.8	51
136	Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. Journal of Psychopharmacology, 2015, 29, 892-897.	2.0	51
137	Kinetic modelling of [¹¹C]PBR28 for 18â€‰kDa translocator protein PET data: A validation study of vascular modelling in the brain using XBD173 and tissue analysis. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 1227-1242.	2.4	51
138	Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA). Schizophrenia Bulletin, 2021, 47, 505-516.	2.3	51
139	Characterization of the anterior cingulate's role in the at-risk mental state using graph theory. NeuroImage, 2011, 56, 1531-1539.	2.1	50
140	In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis. JAMA Psychiatry, 2019, 76, 1074.	6.0	50
141	The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory. Psychopharmacology, 2013, 227, 221-229.	1.5	49
142	Effect of Citalopram on Emotion Processing in Humans: A Combined 5-HT1A [11C]CUMI-101 PET and Functional MRI Study. Neuropsychopharmacology, 2018, 43, 655-664.	2.8	49
143	Brain TSPO imaging and gray matter volume in schizophrenia patients and in people at ultra high risk of psychosis: An [11C]PBR28 study. Schizophrenia Research, 2018, 195, 206-214.	1.1	48
144	Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Human Psychopharmacology, 2012, 27, 15-23.	0.7	47

#	Article	IF	Citations
145	Altered activation and connectivity in a hippocampalâ€“basal gangliaâ€“midbrain circuit during salience processing in subjects at ultra high risk for psychosis. Translational Psychiatry, 2017, 7, e1245-e1245.	2.4	47
146	The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. Molecular Psychiatry, 2021, 26, 1310-1320.	4.1	47
147	Sexual dysfunction in people with prodromal or first-episode psychosis. British Journal of Psychiatry, 2012, 201, 131-136.	1.7	46
148	Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis. Neuropsychopharmacology, 2018, 43, 2652-2659.	2.8	45
149	Facial and Prosodic Emotion Recognition Deficits Associate with Specific Clusters of Psychotic Symptoms in Schizophrenia. PLoS ONE, 2013, 8, e66571.	1.1	45
150	The Predictive Power of Brain mRNA Mappings for in vivo Protein Density: A Positron Emission Tomography Correlation Study. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 827-835.	2.4	44
151	Elevated Striatal Dopamine Function in Immigrants and Their Children: A Risk Mechanism for Psychosis. Schizophrenia Bulletin, 2017, 43, sbw181.	2.3	44
152	Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies. International Journal of Molecular Sciences, 2021, 22, 13185.	1.8	44
153	Dopamine Function in Cigarette Smokers: An [18F]-DOPA PET Study. Neuropsychopharmacology, 2014, 39, 2397-2404.	2.8	43
154	Covariance statistics and network analysis of brain PET imaging studies. Scientific Reports, 2019, 9, 2496.	1.6	42
155	GABA _A receptor availability is not altered in adults with autism spectrum disorder or in mouse models. Science Translational Medicine, 2018, 10, .	5.8	41
156	Functional brain networks before the onset of psychosis: A prospective fMRI study with graph theoretical analysis. NeuroImage: Clinical, 2012, 1, 91-98.	1.4	40
157	Inflammation: its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics. Psychopharmacology, 2014, 231, 317-318.	1.5	40
158	Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World Journal of Biological Psychiatry, 2022, 23, 719-742.	1.3	40
159	The effect of ageing on grey and white matter reductions in schizophrenia. Schizophrenia Research, 2009, 112, 7-13.	1.1	39
160	Magnitude and heterogeneity of brain structural abnormalities in 22q11.2 deletion syndrome: a meta-analysis. Molecular Psychiatry, 2020, 25, 1704-1717.	4.1	39
161	Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia. Schizophrenia Bulletin, 2021, 47, 662-671.	2.3	39
162	Limbic striatal dopamine D2/3 receptor availability is associated with non-planning impulsivity in healthy adults after exclusion of potential dissimulators. Psychiatry Research - Neuroimaging, 2012, 202, 60-64.	0.9	38

#	Article	IF	Citations
163	Striatal Dopamine Transporter Availability in Drug-Naive Patients With Schizophrenia: A Case-Control SPECT Study With [99mTc]-TRODAT-1 and a Meta-Analysis. Schizophrenia Bulletin, 2013, 39, 378-386.	2.3	38
164	The practical management of refractory schizophrenia - the Maudsley Treatment REview and Assessment Team service approach. Acta Psychiatrica Scandinavica, 2014, 130, 427-438.	2.2	38
165	Generalization of endothelial modelling of TSPO PET imaging: Considerations on tracer affinities. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 874-885.	2.4	38
166	Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia. Brain, 2020, 143, 1261-1277.	3.7	38
167	New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics. Neuroscience and Biobehavioral Reviews, 2022, 132, 324-361.	2.9	38
168	A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs, 2022, 36, 659-679.	2.7	38
169	Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patientâ€“Control Differences. Biological Psychiatry, 2021, 89, e5-e8.	0.7	36
170	Presynaptic 5-HT1A is Related to 5-HTT Receptor Density in the Human Brain. Neuropsychopharmacology, 2011, 36, 2258-2265.	2.8	35
171	Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology, 2019, 236, 1985-1997.	1.5	35
172	Very Early Brain Damage Leads to Remodeling of the Working Memory System in Adulthood: A Combined fMRI/Tractography Study. Journal of Neuroscience, 2015, 35, 15787-15799.	1.7	34
173	Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis. Psychological Medicine, 2017, 47, 243-254.	2.7	34
174	Cardiac structure and function in patients with schizophrenia taking antipsychotic drugs: an MRI study. Translational Psychiatry, 2019, 9, 163.	2.4	34
175	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. Neuropsychopharmacology, 2020, 45, 804-810.	2.8	34
176	A potential biomarker for treatment stratification in psychosis: evaluation of an [18F] FDOPA PET imaging approach. Neuropsychopharmacology, 2021, 46, 1122-1132.	2.8	34
177	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹C]IMA107. American Journal of Psychiatry, 2016, 173, 714-721.	4.0	33
178	Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis. Neuroscience and Biobehavioral Reviews, 2020, 119, 255-267.	2.9	33
179	Impaired verbal self-monitoring in individuals at high risk of psychosis. Psychological Medicine, 2010, 40, 1433-1442.	2.7	32
180	Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms. International Journal of Neuropsychopharmacology, 2018, 21, 114-119.	1.0	32

#	Article	IF	Citations
181	Early Detection and Intervention in Bipolar Affective Disorder: Targeting the Development of the Disorder. Current Psychiatry Reports, 2011, 13, 493-499.	2.1	30
182	Quantification of Ligand PET Studies using a Reference Region with a Displaceable Fraction: Application to Occupancy Studies with [11C]-DASB as an Example. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 70-80.	2.4	30
183	Nature or Nurture? Determining the Heritability of Human Striatal Dopamine Function: an [18F]-DOPA PET Study. Neuropsychopharmacology, 2013, 38, 485-491.	2.8	30
184	Glutamate, N-acetyl aspartate and psychotic symptoms in chronic ketamine users. Psychopharmacology, 2014, 231, 2107-2116.	1.5	30
185	The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia. American Journal of Psychiatry, 2017, 174, 421-426.	4.0	30
186	Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic Imaging. Nature Communications, 2019, 10, 4493.	5.8	30
187	Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study. NeuroImage, 2010, 50, 260-266.	2.1	29
188	Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome. Schizophrenia Bulletin, 2020, 46, 670-679.	2.3	29
189	Phasic Stimulation of Midbrain Dopamine Neuron Activity Reduces Salt Consumption. ENeuro, 2018, 5, ENEURO.0064-18.2018.	0.9	29
190	Predicting Brain Occupancy from Plasma Levels using PET: Superiority of Combining Pharmacokinetics with Pharmacodynamics while Modeling the Relationship. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 759-768.	2.4	28
191	Spatial working memory ability in individuals at ultra high risk for psychosis. Journal of Psychiatric Research, 2014, 50, 100-105.	1.5	28
192	Hyperprolactinaemia in first episode psychosis - A longitudinal assessment. Schizophrenia Research, 2017, 189, 117-125.	1.1	28
193	The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole. Translational Psychiatry, 2018, 8, 87.	2.4	28
194	The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 84, 152-159.	2.5	28
195	Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate. NPJ Schizophrenia, 2019, 5, 12.	2.0	28
196	Understanding and Predicting Variability in Response to Treatment in Psychotic Disorders: In Vivo Findings. Clinical Pharmacology and Therapeutics, 2019, 105, 1079-1081.	2.3	28
197	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	2.4	27
198	Tobacco smoking and dopaminergic function in humans: a meta-analysis of molecular imaging studies. Psychopharmacology, 2019, 236, 1119-1129.	1.5	26

#	Article	IF	Citations
199	Understanding the genetics of neuropsychiatric disorders: the potential role of genomic regulatory blocks. Molecular Psychiatry, 2020, 25, 6-18.	4.1	26
200	The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study. Journal of Psychopharmacology, 2020, 34, 981-989.	2.0	26
201	Individual Differences in Response to Antidepressants. JAMA Psychiatry, 2021, 78, 490.	6.0	26
202	The effect of perinatal brain injury on dopaminergic function and hippocampal volume in adult life. ELife, 2017, 6, .	2.8	26
203	Reappraising the variability of effects of antipsychotic medication in schizophrenia: a metaâ€analysis. World Psychiatry, 2022, 21, 287-294.	4.8	26
204	Prevalence of serum N-methyl-d-aspartate receptor autoantibodies in refractory psychosis. British Journal of Psychiatry, 2015, 206, 164-165.	1.7	25
205	Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study. British Journal of Psychiatry, 2019, 215, 712-719.	1.7	25
206	Chronic psychosocial stressors are associated with alterations in salience processing and corticostriatal connectivity. Schizophrenia Research, 2019, 213, 56-64.	1.1	25
207	Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes. Neuropsychopharmacology, 2021, 46, 1468-1474.	2.8	25
208	HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis. Translational Psychiatry, 2016, 6, e797-e797.	2.4	24
209	Prevalence of treatment-resistant psychoses in the community: A naturalistic study. Journal of Psychopharmacology, 2019, 33, 1248-1253.	2.0	24
210	Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models. Cerebral Cortex, 2020, 30, 3573-3589.	1.6	24
211	Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis. Lancet Psychiatry,the, 2021, 8, 589-598.	3.7	24
212	The effects of haloperidol on microglial morphology and translocator protein levels: An in vivo study in rats using an automated cell evaluation pipeline. Journal of Psychopharmacology, 2018, 32, 1264-1272.	2.0	23
213	The relationship between childhood trauma, dopamine release and dexamphetamine-induced positive psychotic symptoms: a [11C]-(+)-PHNO PET study. Translational Psychiatry, 2019, 9, 287.	2.4	23
214	Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis. NPJ Schizophrenia, 2020, 6, 21.	2.0	23
215	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal 18F-DOPA PET and voxel-based morphometry study. Molecular Psychiatry, 2021, 26, 1332-1345.	4.1	23
216	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. Schizophrenia Research: Cognition, 2022, 29, 100249.	0.7	23

#	Article	IF	Citations
217	Targeting glutamate to treat schizophrenia: lessons from recent clinical studies. Psychopharmacology, 2016, 233, 2425-2428.	1.5	22
218	The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders. Neuropsychopharmacology, 2020, 45, 1870-1876.	2.8	22
219	Dopamine and glutamate in individuals at high risk for psychosis: a metaâ€analysis of in vivo imaging findings and their variability compared to controls. World Psychiatry, 2021, 20, 405-416.	4.8	22
220	White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology, 2022, 47, 1413-1420.	2.8	22
221	Economic Impact of Early Detection and Early Intervention of Psychosis. Current Pharmaceutical Design, 2012, 18, 592-595.	0.9	21
222	Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [¹¹C]DASB PET study. Psychological Medicine, 2016, 46, 357-366.	2.7	21
223	The effects of cannabinoid 1 receptor compounds on memory: a meta-analysis and systematic review across species. Psychopharmacology, 2019, 236, 3257-3270.	1.5	21
224	Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study. Neuropsychopharmacology, 2020, 45, 641-648.	2.8	21
225	â€˜Trumanâ€™ signs and vulnerability to psychosis. British Journal of Psychiatry, 2008, 193, 168-168.	1.7	20
226	Further evaluation of the carbon11â€labeled D_{2/3} agonist PET radiotracer PHNO: Reproducibility in tracer characteristics and characterization of extrastriatal binding. Synapse, 2010, 64, 301-312.	0.6	20
227	Delusional ideation, manic symptomatology and working memory in a cohort at clinical high-risk for psychosis: A longitudinal study. European Psychiatry, 2012, 27, 258-263.	0.1	19
228	Presynaptic Serotoninergic Regulation of Emotional Processing: A Multimodal Brain Imaging Study. Biological Psychiatry, 2015, 78, 563-571.	0.7	19
229	Health anxiety in medical students. Lancet, The, 1998, 351, 1332.	6.3	18
230	Partial Volume Correction using Structuralâ€“Functional Synergistic Resolution Recovery: Comparison with Geometric Transfer Matrix Method. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 914-920.	2.4	18
231	The magnitude and variability of brain structural alterations in bipolar disorder: A double meta-analysis of 5534 patients and 6651 healthy controls. Journal of Affective Disorders, 2021, 291, 171-176.	2.0	18
232	Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues in Clinical Neuroscience, 2013, 15, 315-328.	1.8	18
233	Testâ€“retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [11C]MePPEP. NeuroImage, 2014, 97, 151-162.	2.1	17
234	Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study. Scientific Reports, 2019, 9, 8685.	1.6	17

#	Article	IF	Citations
235	Task-induced functional brain connectivity mediates the relationship between striatal D2/3 receptors and working memory. ELife, 2019, 8, .	2.8	17
236	Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of ¹⁸FDG-PET studies in schizophrenia. Psychological Medicine, 2023, 53, 4880-4897.	2.7	17
237	Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study. Schizophrenia Research, 2019, 204, 381-388.	1.1	16
238	Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy caseâ€“control study at 7â€‰T. Translational Psychiatry, 2021, 11, 367.	2.4	16
239	The Effect of Clozapine on Factors Controlling Glucose Homeostasis. Journal of Clinical Psychiatry, 2004, 65, 1352-1355.	1.1	16
240	Associative blocking to reward-predicting cues is attenuated in ketamine users but can be modulated by images associated with drug use. Psychopharmacology, 2013, 225, 41-50.	1.5	15
241	Interpreting the neurodevelopmental hypothesis of schizophrenia in the context of normal brain development and ageing. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2745.	3.3	15
242	Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia. NPJ Schizophrenia, 2019, 5, 6.	2.0	15
243	Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [¹⁸F]DOPA PET and fMRI study. Psychological Medicine, 2019, 49, 2533-2542.	2.7	15
244	Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [18F]DOPA and [11C]raclopride PET study in first-episode psychosis. Molecular Psychiatry, 2021, 26, 3476-3488.	4.1	15
245	Cardiac structure and function in schizophrenia: cardiac magnetic resonance imaging study. British Journal of Psychiatry, 2020, 217, 450-457.	1.7	15
246	Platform for systems medicine research and diagnostic applications in psychotic disordersâ€”The METSY project. European Psychiatry, 2018, 50, 40-46.	0.1	14
247	A Unified Framework for Plasma Data Modeling in Dynamic Positron Emission Tomography Studies. IEEE Transactions on Biomedical Engineering, 2019, 66, 1447-1455.	2.5	14
248	The acute effects of cannabidiol on the neural correlates of reward anticipation and feedback in healthy volunteers. Journal of Psychopharmacology, 2020, 34, 969-980.	2.0	14
249	Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis. Neuropsychopharmacology, 2021, 46, 1484-1493.	2.8	14
250	Challenges in CNS drug development and the role of imaging. Psychopharmacology, 2021, 238, 1229-1230.	1.5	14
251	N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study. Translational Psychiatry, 2021, 11, 425.	2.4	14
252	The Role of White Matter Abnormalities in Treatment-Resistant Depression: A Systematic Review. Current Pharmaceutical Design, 2015, 21, 1337-1346.	0.9	14

#	Article	IF	Citations
253	manongarivo Environmentally friendly health care begins in Madagascar. Lancet, The, 1998, 351, 577.	6.3	13
254	Cognitive therapy: at last an alternative to antipsychotics?. Lancet, The, 2014, 383, 1364-1366.	6.3	13
255	Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis. Psychiatry Research, 2016, 238, 270-276.	1.7	13
256	An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications. Comprehensive Psychiatry, 2016, 66, 39-45.	1.5	13
257	The effect of a genetic variant at the schizophrenia associated AS3MT/BORCS7 locus on striatal dopamine function: A PET imaging study. Psychiatry Research - Neuroimaging, 2019, 291, 34-41.	0.9	13
258	Striatal dopaminergic alterations in individuals with copy number variants at the 22q11.2 genetic locus and their implications for psychosis risk: a [18F]-DOPA PET study. Molecular Psychiatry, 2023, 28, 1995-2006.	4.1	13
259	Dopaminergic organization of striatum is linked to cortical activity and brain expression of genes associated with psychiatric illness. Science Advances, 2021, 7, .	4.7	13
260	Automated Data Quality Control in FDOPA brain PET Imaging using Deep Learning. Computer Methods and Programs in Biomedicine, 2021, 208, 106239.	2.6	13
261	The use of healthy volunteers instead of patients to inform drug dosing studies: a [11C]raclopride PET study. Psychopharmacology, 2011, 217, 515-523.	1.5	12
262	Amygdala reactivity in ethnic minorities and its relationship to the social environment: an fMRI study. Psychological Medicine, 2018, 48, 1985-1992.	2.7	12
263	Alendronic Acid for Antipsychotic-Related Osteopenia. American Journal of Psychiatry, 2004, 161, 756-756.	4.0	11
264	Sensory gating deficits in the attenuated psychosis syndrome. Schizophrenia Research, 2015, 161, 277-282.	1.1	11
265	Neural Responsivity to Food Cues in Patients With Unmedicated First-Episode Psychosis. JAMA Network Open, 2019, 2, e186893.	2.8	11
266	Comment on â€œIn Vivo [¹⁸F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primatesâ€• ACS Chemical Neuroscience, 2019, 10, 768-772.	1.7	11
267	The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. Journal of Affective Disorders, 2020, 276, 991-1000.	2.0	11
268	The Topography of Striatal Dopamine and Symptoms in Psychosis: An Integrative Positron Emission Tomography and Magnetic Resonance Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1040-1051.	1.1	11
269	Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 677-687.	1.8	11
270	Hyperprolactinaemia caused by antipsychotic drugs. BMJ: British Medical Journal, 2002, 324, 1278-1278.	2.4	11

#	Article	IF	Citations
271	The role of mitochondria in the pathophysiology of schizophrenia: A critical review of the evidence focusing on mitochondrial complex one. Neuroscience and Biobehavioral Reviews, 2022, 132, 449-464.	2.9	11
272	Response to Narendran and Frankle: The Interpretation of PET Microglial Imaging in Schizophrenia. American Journal of Psychiatry, 2016, 173, 537-538.	4.0	10
273	The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study. Molecular Psychiatry, 2021, 26, 4464-4474.	4.1	10
274	The Cannabinoid CB1 Receptor in Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 646-659.	1.1	10
275	Glutamate connectivity associations converge upon the salience network in schizophrenia and healthy controls. Translational Psychiatry, 2021, 11, 322.	2.4	10
276	Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behavioural Brain Research, 2021, 405, 113203.	1.2	10
277	Emerging Treatments in Schizophrenia. Journal of Clinical Psychiatry, 2022, 83, .	1.1	10
278	Adipose tissue dysfunction, inflammation, and insulin resistance: alternative pathways to cardiac remodelling in schizophrenia. A multimodal, caseâ€“control study. Translational Psychiatry, 2021, 11, 614.	2.4	10
279	Individual and combined effects of cannabidiol and Î”⁹-tetrahydrocannabinol on striato-cortical connectivity in the human brain. Journal of Psychopharmacology, 2022, 36, 732-744.	2.0	10
280	The Relationship Between Prolactin Levels and Glucose Homeostasis in Antipsychotic-treated Schizophrenic Patients. Journal of Clinical Psychopharmacology, 2006, 26, 629-631.	0.7	9
281	Longitudinal PET Imaging in a Patient With Schizophrenia Did Not Show Marked Changes in Dopaminergic Function With Relapse of Psychosis. American Journal of Psychiatry, 2008, 165, 1613-1614.	4.0	9
282	Single cocaine exposure does not alter striatal preâ€synaptic dopamine function in mice: an [¹⁸F]â€<scp>FDOPA PET</scp> study. Journal of Neurochemistry, 2017, 143, 551-560.	2.1	9
283	Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [11C]DASB PK-PD Study. Clinical Pharmacokinetics, 2017, 56, 371-381.	1.6	9
284	Higher serotonin transporter availability in earlyâ€onset obsessiveâ€“compulsive disorder patients undergoing escitalopram treatment: A [¹¹C]DASB PET study. Human Psychopharmacology, 2018, 33, e2642.	0.7	9
285	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. Frontiers in Neurology, 2020, 11, 541377.	1.1	9
286	Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis. Schizophrenia Bulletin, 2021, 47, 160-169.	2.3	9
287	The acute effects of cannabidiol on emotional processing and anxiety: a neurocognitive imaging study. Psychopharmacology, 2022, 239, 1539-1549.	1.5	9
288	Calculating Occupancy when One does not have Baseline: A Comparison of Different Options. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 1760-1767.	2.4	8

#	Article	IF	Citations
289	The effect of the DISC1 Ser704Cys polymorphism on striatal dopamine synthesis capacity: an [18F]-DOPA PET study. Human Molecular Genetics, 2018, 27, 3498-3506.	1.4	8
290	Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis. Frontiers in Psychiatry, 2019, 10, 254.	1.3	8
291	Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion. European Neuropsychopharmacology, 2019, 29, 1333-1342.	0.3	8
292	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. Psychopharmacology, 2022, 239, 3439-3445.	1.5	8
293	The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. Focus (American Psychiatric Publishing), 2020, 18, 456-465.	0.4	8
294	Dopamine partial agonists and prodopaminergic drugs for schizophrenia: Systematic review and meta-analysis of randomized controlled trials. Neuroscience and Biobehavioral Reviews, 2022, 135, 104568.	2.9	8
295	An overview of functional, structural and neurochemical imaging studies in individuals with a clinical high risk for psychosis. Neuropsychiatry, 2011, 1, 477-493.	0.4	7
296	The relationship between reward and punishment processing and the 5-HT1A receptor as shown by PET. Psychopharmacology, 2014, 231, 2579-2586.	1.5	7
297	Optimising treatment of schizophrenia: the role of adjunctive fluvoxamine. Psychopharmacology, 2016, 233, 739-740.	1.5	7
298	Schizophrenia: inorganic no more. Lancet Psychiatry,the, 2016, 3, 600-602.	3.7	7
299	Assessing the impact of different penalty factors of the Bayesian reconstruction algorithm Q.Clear on in vivo low count kinetic analysis of [11C]PHNO brain PET-MR studies. EJNMMI Research, 2022, 12, 11.	1.1	7
300	Low COVIDâ€19 vaccination rates in people with severe mental illness and reasons for this: An outâ€patient study. Acta Psychiatrica Scandinavica, 2022, 145, 416-418.	2.2	7
301	Pharmacoterrorism: the potential role of psychoactive drugs in the Paris and Tunisian attacks. Psychopharmacology, 2016, 233, 933-935.	1.5	6
302	Translation and cross-cultural adaptation of the Sexual Function Questionnaire (SFQ) into Brazilian Portuguese. Trends in Psychiatry and Psychotherapy, 2017, 39, 110-115.	0.4	6
303	The association of psychosocial risk factors for mental health with a brain marker altered by inflammation: A translocator protein (TSPO) PET imaging study. Brain, Behavior, and Immunity, 2019, 80, 742-750.	2.0	6
304	Positive symptom phenotypes appear progressively in â€œEDiPSâ€ a new animal model of the schizophrenia prodrome. Scientific Reports, 2021, 11, 4294.	1.6	6
305	Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia. NPJ Schizophrenia, 2022, 8, 13.	2.0	6
306	Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study. British Journal of Psychiatry, 2022, 221, 740-747.	1.7	6

#	Article	IF	Citations
307	Comment on Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Current Medical Research and Opinion, 2004, 20, 1649-1649.	0.9	5
308	Multimodal functional imaging investigation before and after the onset of psychosis. International Journal of Neuropsychopharmacology, 2009, 12, 579.	1.0	5
309	Is clinical intervention in the ultra high risk phase effective?. Revista Brasileira De Psiquiatria, 2011, 33, s161-s174.	0.9	5
310	Need for care, adversity exposure and perceived stress in clinical and healthy voice-hearers. Psychological Medicine, 2021, 51, 1944-1950.	2.7	5
311	Manic psychosis induced by long term alpha-interferon treatment for hepatitis C. International Journal of Psychiatry in Clinical Practice, 2000, 4, 161-162.	1.2	5
312	Julius Wagner-Jauregg, 1857â€“1940. American Journal of Psychiatry, 2009, 166, 409-409.	4.0	4
313	Does human presynaptic striatal dopamine function predict social conformity?. Journal of Psychopharmacology, 2014, 28, 237-243.	2.0	4
314	Treatment-Resistant Schizophrenia in a Patient With 17q12 Duplication. Biological Psychiatry, 2016, 80, e19-e20.	0.7	4
315	The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis. Neuropsychopharmacology, 2018, 43, 1195-1196.	2.8	4
316	Trends in mortality in schizophrenia and their implications. Acta Psychiatrica Scandinavica, 2018, 138, 489-491.	2.2	4
317	Parametric Mapping for TSPO PET Imaging with Spectral Analysis Impulsive Response Function. Molecular Imaging and Biology, 2021, 23, 560-571.	1.3	4
318	Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3530-3539.	3.3	4
319	Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function. Translational Psychiatry, 2021, 11, 579.	2.4	4
320	Variability of glucose, insulin, and lipid disturbances in first-episode psychosis: a meta-analysis. Psychological Medicine, 2023, 53, 3150-3156.	2.7	4
321	Striatal dopamine synthesis capacity and its association with negative symptoms upon resolution of positive symptoms in first-episode schizophrenia and delusional disorder. Psychopharmacology, 2022, 239, 2133-2141.	1.5	4
322	Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophrenia Research, 2004, 66, 77-78.	1.1	3
323	Serum glutamic acid decarboxylase 65 antibody levels in people with schizophrenia and their families. Schizophrenia Research, 2005, 73, 379-381.	1.1	3
324	Understanding pathophysiology is crucial in linking clinical staging to targeted theraâ€peutics. World Psychiatry, 2008, 7, 162-163.	4.8	3

#	Article	IF	Citations
325	Letter to the Editor: Mind the translation gap: problems in the implementation of early intervention services. Psychological Medicine, 2010, 40, 171-172.	2.7	3
326	Optimising treatment of refractory schizophrenia. Psychopharmacology, 2013, 227, 373-374.	1.5	3
327	Immune influences on the brain: new findings and implications for treatment. Psychopharmacology, 2016, 233, 1539-1541.	1.5	3
328	Editorial: Reporting guidelines for psychopharmacology. Psychopharmacology, 2016, 233, 1131-1134.	1.5	3
329	The effects of voice content on stress reactivity: A simulation paradigm of auditory verbal hallucinations. Schizophrenia Research, 2019, , .	1.1	3
330	Striatal dopamine D2/3 receptors in medication-naÃ¯ve schizophrenia: an [123I] IBZM SPECT study. Psychological Medicine, 2021, , 1-9.	2.7	3
331	Acute acetate administration increases endogenous opioid levels in the human brain: A [¹¹C]carfentanil molecular imaging study. Journal of Psychopharmacology, 2021, 35, 606-610.	2.0	3
332	Pseudohallucinations Versus True Hallucinations in Prodromal Psychosis. Journal of Clinical Psychiatry, 2009, 70, 1056-1057.	1.1	3
333	Hyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessed. BMJ, The, 2002, 324, 1278.	3.0	3
334	Animal Models of Relevance to the Schizophrenia Prodrome. Biological Psychiatry Global Open Science, 2023, 3, 22-32.	1.0	3
335	Street slang and schizophrenia. BMJ: British Medical Journal, 2007, 335, 1294-1294.	2.4	2
336	Functionally defined regions may aid interpretation of striatal dopamine elevation in schizophrenia. Schizophrenia Research, 2009, 109, 200.	1.1	2
337	Antipsychotic drugs for prevention of relapse. Lancet, The, 2012, 379, 2030-2031.	6.3	2
338	Poster #126 DOPAMINERGIC FUNCTION IN TREATMENT RESISTANT SCHIZOPHRENIA: NEW EVIDENCE FROM AN [18]-DOPA PET STUDY. Schizophrenia Research, 2012, 136, S137.	1.1	2
339	Commentary on a study of the prevalence of mental disorders by Breslau etÂal.. Journal of Psychiatric Research, 2015, 61, 231-232.	1.5	2
340	S19. EVIDENCE OF THE LIPID PARADOX IN PSYCHOSIS: A META-ANALYSIS OF CHOLESTEROL AND TRIGLYCERIDE LEVELS IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S330-S330.	2.3	2
341	F227. The State or Trait Component of Dopamine and Glutamate Dysfunction in the Risk for Psychosis: An in Vivo Multimodal Imaging Study of Individuals With 22q11 Deletion. Biological Psychiatry, 2018, 83, S327.	0.7	2
342	32.4 A NOVEL TREATMENT FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA BY ENHANCING THE ACTIVITY OF PARVALBUMIN INTERNEURONS. Schizophrenia Bulletin, 2019, 45, S142-S143.	2.3	2

#	Article	IF	Citations
343	Integrated metastate functional connectivity networks predict change in symptom severity in clinical high risk for psychosis. Human Brain Mapping, 2021, 42, 439-451.	1.9	2
344	Magnitude and variability of structural brain abnormalities in neuropsychiatric disease: protocol for a network meta-analysis of MRI studies. Evidence-Based Mental Health, 2021, 24, 111-114.	2.2	2
345	Translation From Genes to Mechanism in Schizophrenia: Are Immuneâ€“Synaptic Interactions the Missing Link?. Biological Psychiatry, 2021, 90, 593-595.	0.7	2
346	Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study. BMJ Open, 2021, 11, e054160.	0.8	2
347	The relationship between glutamate, dopamine, and cortical gray matter: A simultaneous PET-MR study. Molecular Psychiatry, 2022, 27, 3493-3500.	4.1	2
348	Comments on "Prolactin Levels and Erectile Function in Patients Treated With Risperidone" (J Clin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.7	1
349	Sex Hormone Augmentation as an Adjunctive Treatment in Schizophrenia. Journal of Clinical Psychopharmacology, 2009, 29, 195-196.	0.7	1
350	Mind the mortality gap: the importance of metabolic function in mental illnesses. Psychopharmacology, 2013, 230, 1-2.	1.5	1
351	Magnetic Resonance and Molecular Imaging in Psychiatry. , 2015, , 439-445.		1
352	First-Episode Schizophrenia and Diabetes Riskâ€”Reply. JAMA Psychiatry, 2017, 74, 763.	6.0	1
353	287. Neuroadaptations to Chronic Ketamine Exposure: A Parallel Human and Mouse MRI Imaging Study. Biological Psychiatry, 2017, 81, S118.	0.7	1
354	F229. Cannabinoid 1 Receptor and Memory Function in First Episode Psychosis: A Multi-Modal PET-fMRI Study. Biological Psychiatry, 2018, 83, S327-S328.	0.7	1
355	S181. THE STATE OR TRAIT COMPONENT OF DOPAMINE AND GLUTAMATE DYSFUNCTION IN THE RISK FOR PSYCHOSIS: AN IN VIVO MULTIMODAL IMAGING STUDY OF INDIVIDUALS WITH 22Q11.2 DELETION. Schizophrenia Bulletin, 2018, 44, S395-S395.	2.3	1
356	Treatment of First-Episode Schizophrenia in a Young Woman. JAMA Psychiatry, 2020, 77, 211.	6.0	1
357	T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS. Schizophrenia Bulletin, 2020, 46, S248-S249.	2.3	1
358	Clozapine and COVID-19: The authors respond. Journal of Psychiatry and Neuroscience, 2020, 45, E1-E2.	1.4	1
359	The Effects of Acute Î”9-Tetrahydrocannabinol on Striatal Glutamatergic Function: A Proton Magnetic Resonance Spectroscopy Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 660-667.	1.1	1
360	Brain volume in chronic ketamine users â€" relationship to sub-threshold psychotic symptoms and relevance to schizophrenia. Psychopharmacology, 2021, , 1.	1.5	1

#	Article	IF	Citations
361	Psychophysiological stress-reactivity in clinical and non-clinical voice-hearers. Schizophrenia Research, 2021, 235, 52-59.	1.1	1
362	Pattern of predictive features of continued cannabis use in patients with recent-onset psychosis and clinical high-risk for psychosis. NPJ Schizophrenia, 2022, 8, 19.	2.0	1
363	A cross-sectional MR study of body fat volumes and distribution in chronic schizophrenia. NPJ Schizophrenia, 2022, 8, 24.	2.0	1
364	Cell line specific alterations in genes associated with dopamine metabolism and signaling in midbrain dopaminergic neurons derived from 22q11.2 deletion carriers with elevated dopamine synthesis capacity. Schizophrenia Research, 2022, , .	1.1	1
365	Impaired verbal memory function is related to anterior cingulate glutamate levels in schizophrenia: findings from the STRATA study. , 2022, 8, .		1
366	Relationship Between Replay-Associated Ripples and Hippocampal N-Methyl-D-Aspartate Receptors: Preliminary Evidence From a PET-MEG Study in Schizophrenia. Schizophrenia Bulletin Open, 2022, 3, .	0.9	1
367	Reply to: Hippocampal Glutamate Levels and Striatal Dopamine D2/3 Receptor Occupancy in Subjects at Ultra High Risk of Psychosis. Biological Psychiatry, 2011, 70, e3-e4.	0.7	0
368	Poster #203 THE RELATIONSHIP BETWEEN ANTIPSYCHOTIC D2 OCCUPANCY AND CHANGE IN FRONTAL METABOLIC AND COGNITIVE FUNCTION: A DUAL [18C]-RACLOPRIDE AND [18F]-FDG STUDY WITH ARIPIPRAZOLE. Schizophrenia Research, 2012, 136, S353-S354.	1.1	0
369	ALTERATIONS IN BRAIN STRUCTURE, FUNCTION AND CHEMISTRY PRIOR TO THE ONSET OF PSYCHOSIS. Schizophrenia Research, 2012, 136, S55.	1.1	0
370	Poster #180 VITAMIN D DEFICIENCY IN FIRST EPISODE PSYCHOSIS. Schizophrenia Research, 2012, 136, S155-S156.	1.1	0
371	Poster #30 DOPAMINE SYNTHESIS CAPACITY IN REGULAR CANNABIS USERS WHO EXPERIENCE TRANSIENT PSYCHOTIC SYMPTOMS ON CANNABIS: AN [F]-DOPA PET IMAGING STUDY. Schizophrenia Research, 2012, 136, S196.	1.1	0
372	Molecular Imaging in Schizophrenia. Neuromethods, 2012, , 305-321.	0.2	0
373	Authors' reply. British Journal of Psychiatry, 2013, 202, 238-238.	1.7	0
374	Authors' reply. British Journal of Psychiatry, 2013, 202, 155-155.	1.7	0
375	OUTCOME IN SUBJECTS AT ULTRA HIGH RISK OF PSYCHOSIS: RELATIONSHIP TO DOPAMINERGIC FUNCTION. Schizophrenia Research, 2014, 153, S18.	1.1	0
376	Does environmental confounding mask pleiotropic effects of a multiple sclerosis susceptibility variant on vitamin D in psychosis?. NPJ Schizophrenia, 2015, 1, 15036.	2.0	0
377	Consistent biological findings in major depression: Results from serotonin transporter meta-analyses. Journal of Affective Disorders, 2016, 199, 171.	2.0	0
378	Ethnicity, the amygdala, and the social environment: a neuroimaging study. Lancet, The, 2017, 389, S67.	6.3	0

#	Article	IF	Citations
379	275. Glutamate in Psychosis: In Vivo Evidence of Its Role in Treatment Response and the Potential to Modulate Glutamatergic Function. Biological Psychiatry, 2017, 81, S113.	0.7	0
380	282. Amygdala Reactivity in Ethnic Minority Individuals, and Its Relationship to the Social Environment. Biological Psychiatry, 2017, 81, S116.	0.7	0
381	731. Biomarkers of Genetic and Environmental Psychosis Risk: Dopamine and Glutamate Imaging. Biological Psychiatry, 2017, 81, S296.	0.7	0
382	79. The Effects of Repeated NMDA Blockade with Ketamine on Dopamine and Glutamate Function. Biological Psychiatry, 2017, 81, S33.	0.7	0
383	249. Dopaminergic and Glutamatergic Function in Bipolar Disorder and Schizophrenia and Treatment Response: PET and MRS Evidence in Drug Naive Patients. Biological Psychiatry, 2018, 83, S100-S101.	0.7	0
384	F18. IS SCHIZOPHRENIA A MULTI-SYSTEM DISORDER? CONSIDERING NEUROLOGICAL, IMMUNE, CARDIOMETABOLIC, AND ENDOCRINE ALTERATIONS IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S225-S226.	2.3	0
385	O7.1. MIDBRAIN DOPAMINE NEURON ACTIVITY CONTROLS THE EFFECTS OF REPEATED KETAMINE ON STRIATAL DOPAMINERGIC FUNCTION. Schizophrenia Bulletin, 2018, 44, S93-S93.	2.3	0
386	F226. The Relationship Between Cortical Glutamate and Striatal Dopamine Function in Psychosis: A Multi-Modal PET and MRS Imaging Study in First Episode Psychosis. Biological Psychiatry, 2018, 83, S326-S327.	0.7	0
387	O2.1. CIRCUIT MECHANISM MEDIATES THE EFFECTS OF SUB-CHRONIC KETAMINE ON STRIATAL DOPAMINE SYNTHESIS CAPACITY AND LOCOMOTOR ACTIVITY: A COMBINED CHEMOGENETICS/PET STUDY. Schizophrenia Bulletin, 2019, 45, S162-S162.	2.3	0
388	Disruptedâ€inâ€schizophrenia 1 functional polymorphisms and D 2 /D 3 receptor availability: A [11 C]â€(+)â€PHNO imaging study. Genes, Brain and Behavior, 2019, 18, e12596.	1.1	0
389	O13.5. GLUTAMATERGIC METABOLITES ASSOCIATED WITH ALTERED HIPPOCAMPAL AND STRIATAL ACTIVATION DURING NOVELTY SALIENCE IN PEOPLE WITH A CLINICAL HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S202-S203.	2.3	0
390	F107. THE EFFECTS OF DEVELOPMENTAL STRESS AND TRAUMA ON THE DOPAMINE SYSTEM. Schizophrenia Bulletin, 2019, 45, S294-S294.	2.3	0
391	O7.6. GABAA RECEPTOR AVAILABILITY IN PATIENTS WITH SCHIZOPHRENIA: A PET STUDY USING [11C]-RO15. Schizophrenia Bulletin, 2019, 45, S181-S182.	2.3	0
392	20.2 CANNABINOID 1 RECEPTOR AVAILABILITY AND MEMORY FUNCTION IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET AND FUNCTIONAL MRI IMAGING STUDY. Schizophrenia Bulletin, 2019, 45, S122-S122.	2.3	0
393	41.2 THE EFFECTS OF DEVELOPMENTAL STRESS AND TRAUMA ON THE DOPAMINE SYSTEM. Schizophrenia Bulletin, 2019, 45, S156-S156.	2.3	0
394	F80. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS: PET AND MR IMAGING FINDINGS IN FIRST EPISODE AND CHRONIC SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S284-S284.	2.3	0
395	S84. THE EFFECT OF ANTIPSYCHOTICS ON GLUTAMATE LEVELS IN THE ANTERIOR CINGULATE AND CLINICAL RESPONSE MEASURED BY PANSS: A 1H-MRS STUDY IN FIRST-EPISODE PSYCHOSIS PATIENTS. Schizophrenia Bulletin, 2019, 45, S339-S339.	2.3	0
396	O5.6. REMISSION FROM ANTIPSYCHOTIC TREATMENT IN FIRST EPISODE PSYCHOSIS RELATED TO LONGITUDINAL CHANGES IN BRAIN GLUTAMATE LEVELS. Schizophrenia Bulletin, 2019, 45, S175-S175.	2.3	0

#	Article	IF	Citations
397	O7.3. ALTERED HIPPOCAMPAL-STRIATAL-MIDBRAIN FUNCTION IN SUBJECTS AT CLINICAL HIGH RISK OF PSYCHOSIS. Schizophrenia Bulletin, 2019, 45, S180-S180.	2.3	0
398	T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S238-S238.	2.3	0
399	T79. BALANCING EFFECTS WITH SIDE-EFFECTS: EXAMINING COMPARATIVE METABOLIC CONSEQUENCES OF 18 ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA USING NETWORK META-ANALYSIS. Schizophrenia Bulletin, 2020, 46, S261-S262.	2.3	0
400	M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S198-S198.	2.3	0
401	S153. IMPAIRED THETA PHASE-COUPLING BETWEEN HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S94-S94.	2.3	0
402	S172. GLUTAMATE RELATED CONNECTIVITY DISTURBANCES OF THE SALIENCE AND DEFAULT MODE NETWORKS IN PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S102-S103.	2.3	0
403	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. Schizophrenia Bulletin, 2020, 46, S28-S28.	2.3	0
404	Drugs to Treat Schizophrenia and Psychosis (Dopamine Antagonists and Partial Agonists Other Than) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		0
405	Integrating the Epidemiology and Pathogenesis of Schizophrenia from the Street to the Striatum: Integrating the Epidemiology and Pathogenesis of Schizophrenia. , 2010, , 357-366.		0
406	Dopamine and the Biology and Course of Treatment Resistance. , 2014, , 31-43.		0
407	M149. THE TOPOGRAPHY OF STRIATAL DOPAMINE AND SYMPTOMS IN PSYCHOSIS: AN INTEGRATIVE PET AND MRI STUDY. Schizophrenia Bulletin, 2020, 46, S192-S192.	2.3	0
408	Vitamin D and cardiometabolic outcomes in first episode psychosis (FEP): A prospective cohort study. Schizophrenia Research, 2022, 246, 26-29.	1.1	0